公司概述
Haemonetics Corporation operates as a medical technology enterprise that provides a comprehensive suite of hospital technology solutions, specifically focusing on automated plasma collection systems, donor management software, and supporting software solutions like NexSys PCS and PCS2, both within the United States and internationally. The company functions within the healthcare sector and the medical devices industry, positioning itself to address critical needs in blood plasma processing and donor tracking across global markets. In terms of scale, Haemonetics maintains a market capitalization of $2.73 billion, generates annual revenue of $1.32 billion, and employs a workforce of 3,023 individuals. These financial dimensions and operational metrics indicate that the company holds a substantial presence in the specialized plasma collection market, reflecting a mature business model with significant installed base and recurring revenue potential derived from its extensive network of hospital clients.
财务健康
The company reported a trailing twelve-month revenue of $1.32 billion with a corresponding net income of $175.44 million and an EBITDA of $364.90 million, illustrating a distinct gap between top-line revenue and bottom-line earnings that reveals a substantial cost structure involving cost of goods sold, operating expenses, and taxes. Beyond net income, the firm generated free cash flow of $335.05 million, which signifies strong financial flexibility to fund operations, service existing debt obligations, or pursue strategic capital allocation without immediate reliance on external financing. Profitability analysis across three key margins shows a gross margin of 60.2%, an operating margin of 21.0%, and a profit margin of 13.3%, where the high gross margin reflects the capital-intensive nature of plasma collection hardware while the spread to operating and profit margins highlights the significant scale of operational overhead and tax burdens. Regarding leverage, total debt stands at $1.23 billion against cash reserves of $363.56 million, resulting in a debt-to-equity ratio of 134.40, which characterizes the balance sheet as highly leveraged given that debt significantly exceeds liquid cash holdings. Liquidity position is assessed via a current ratio of 1.75, indicating that current assets are more than 1.75 times current liabilities and suggesting adequate coverage for short-term obligations despite the high leverage profile. Return metrics demonstrate a return on equity of 19.3% and a return on assets of 6.4%, revealing that management is generating efficient returns on shareholder equity while asset turnover remains moderate relative to the equity base.
估值评估
Valuation multiples for Haemonetics include a trailing P/E ratio of 16.09 and a forward P/E of 11.01, where the notable contraction between these figures implies an expectation of significant earnings acceleration in future periods relative to current performance. The price-to-book ratio stands at 3.00, indicating that the market prices the company at three times its book value, suggesting a premium assigned to its intangible assets, proprietary technology, and market position beyond the tangible capital employed. Alternative valuation perspectives are provided by a price-to-sales ratio of 2.07 and an EV/EBITDA of 9.80, which collectively suggest the stock is priced reasonably relative to revenue and earnings power when adjusted for enterprise value. Price action over the last year is bounded by a 52-week high of $87.32 and a 52-week low of $47.32, and without the specific current share price in the provided facts, the relative trading position can only be described as fluctuating within this established volatility range. The stock exhibits a beta of 0.36, which indicates that its price volatility is substantially lower than the broader market, behaving as a defensive position that moves less aggressively than the overall equity index during market swings.
Growth & Income
Growth dynamics are defined by a revenue growth rate of -2.7% year-over-year contrasted with an earnings growth rate of 28.4% year-over-year, demonstrating that earnings are expanding at a pace significantly faster than revenue, likely driven by margin expansion, cost efficiencies, or favorable product mix rather than top-line volume growth. Regarding income distribution, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute dividends to shareholders and retains all earnings for internal reinvestment. This retention strategy aligns with the non-dividend payer profile, allowing the firm to reinvest earnings into research and development, capital expenditures, and debt reduction rather than paying out cash to investors. Consequently, the overall growth and income profile presents a scenario of capital appreciation potential driven by earnings per share expansion and operational leverage, devoid of current income yield support.